Cargando…

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer

The majority of breast cancer tumors are estrogen receptor-positive (ER(+)) and can be treated with endocrine therapy. However, certain patients may exhibit a good prognosis without systemic treatment. The aim of the present study was to identify novel prognostic factors for patients with ER(+) brea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fohlin, Helena, Bekkhus, Tove, Sandström, Josefine, Fornander, Tommy, Nordenskjöld, Bo, Carstensen, John, Stål, Olle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923975/ https://www.ncbi.nlm.nih.gov/pubmed/31897114 http://dx.doi.org/10.3892/ol.2019.11109

Ejemplares similares

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
por: Hilborn, Erik, et al.
Publicado: (2016)

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
por: Hilborn, Erik, et al.
Publicado: (2014)

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
por: Sivik, Tove, et al.
Publicado: (2012)

IP6K2 predicts favorable clinical outcome of primary breast cancer
por: Sandström, Josefine, et al.
Publicado: (2021)

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
por: Dar, Huma, et al.
Publicado: (2021)

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
por: Nordenskjöld, Anna, et al.
Publicado: (2023)

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
por: Karlsson, Elin, et al.
Publicado: (2018)

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
por: Johansson, Annelie, et al.
Publicado: (2022)

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Schroeder, Brock, et al.
Publicado: (2017)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010)

Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer
por: Johansson, Henrik J, et al.
Publicado: (2015)

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer
por: Chan, Melissa, et al.
Publicado: (2015)

Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.
por: Stål, O., et al.
Publicado: (1992)

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
por: Karlsson, Elin, et al.
Publicado: (2013)

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype
por: Veenstra, Cynthia, et al.
Publicado: (2019)

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer
por: Lindström, Linda S, et al.
Publicado: (2018)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
por: Hefti, Marco M, et al.
Publicado: (2013)

Expression of Progesterone Receptor A as an Independent Negative Prognosticator for Cervical Cancer
por: Garrido, Fabian, et al.
Publicado: (2023)

Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer
por: Mehmeti, Meliha, et al.
Publicado: (2015)

Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer
por: Fan, Ying, et al.
Publicado: (2015)

Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors
por: Wiebe, John P, et al.
Publicado: (2013)

Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2015)

Prognostic value of estrogen receptor-α and progesterone receptor in curatively resected colorectal cancer: a retrospective analysis with independent validations
por: Ye, Shu-Biao, et al.
Publicado: (2019)

High Expression of Sphingosine Kinase 1 in Estrogen and Progesterone Receptors-Negative Breast Cancer
por: Nazouri, Azadeh-Sadat, et al.
Publicado: (2017)

Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer
por: Wang, Caifeng, et al.
Publicado: (2020)

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
por: Liu, Xi-Yu, et al.
Publicado: (2018)

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer
por: Park, Chansub, et al.
Publicado: (2016)

Progesterone receptor modulates estrogen receptor-α action in breast cancer
por: Mohammed, Hisham, et al.
Publicado: (2015)

Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients
por: Yang, Li-Heng, et al.
Publicado: (2012)

A model of spontaneous mouse mammary tumor for human estrogen receptor- and progesterone receptor-negative breast cancer
por: ZHENG, LIXIANG, et al.
Publicado: (2014)

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
por: Hackshaw, Allan, et al.
Publicado: (2009)

Estrogen Receptor Mutations and Changes in Estrogen Receptor and Progesterone Receptor Protein Expression in Metastatic or Recurrent Breast Cancer
por: Umekita, Yoshihisa, et al.
Publicado: (1998)

Progesterone and Estrogen Receptors in Neurofibromas of Patients with NF1
por: Geller, Mauro, et al.
Publicado: (2008)

Estrogen and Progesterone Receptors in Endometrium in Women with Unexplained Infertility
por: Godinjak, Zulfo, et al.
Publicado: (2014)

Distribution of estrogen and progesterone receptors isoforms in endometrial cancer
por: Kreizman-Shefer, Hila, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_trhaji1nspumart8jalu7ffl6j